Table 7.
Reference | Year | Treatment regimen | Median survival (mo) | p | HR | 95% CI |
Berlin | 2002 | Gemcitabine | 5.4 | 0.09 | 0.82 | 0.65 – 1.03 |
Gemcitabine + 5-FU (bolus) | 6.7 | |||||
Riess | 2005 | Gemcitabine | 6.2 | 0.68 | 1.04 | 0.86 – 1.25 |
Gemcitabine + 5-FU (infusional) | 5.9 | |||||
DiCostanzo | 2005 | Gemcitabine | 7.8 | -- | na | na |
Gemcitabine + 5-FU (CI) | 7.5 | |||||
Scheithauer | 2003 | Gemcitabine | 8.2 | -- | 0.82 | 0.50 – 1.35 |
Gemcitabine + Capecitabine | 9.5 | |||||
Herrmann | 2005 | Gemcitabine | 7.3 | 0.314 | 0.89 | 0.70 – 1.12 |
Gemcitabine + Capecitabine | 8.4 | |||||
Cunningham | 2005 | Gemcitabine | 6.0 | 0.026 | 0.79 | 0.65 – 0.97 |
Gemcitabine + Capecitabine | 7.4 |
5-FU: 5-fluorouracil; CI = continuous infusion; na = data not available;